PeDRA advocates for better access to treatments for children with dermatology diseases. Click here to read PeDRA’s position statement submitted to the FDA on patient-focused drug development for psoriasis: PeDRA position on psoriasis drug development
PeDRA is a major sponsor of the FDA Guidance Document for Industry (GDI), guidelines on developing new therapeutic agents for treatment of atopic dermatitis in children and adolescents. Click here for an update on the progress of this important project.
March 2016 GDI Update
PeDRA has made marked strides since its inception in 2012, already having impact on the volume and quality of research studies being performed in the field of pediatric dermatology. Background, early successes and areas of focus can be found in the organization’s Annual Report.
2016 Update Report
The PeDRA Post, PeDRA’s e-newsletterPeDRA’s twice yearly e-newsletter tracks progress being made in studies underway and recruits new study members in various areas of research. In each issue, the e-newsletter also highlights a patient advocacy organization engaged with PeDRA, as well as profiling special donors who have made possible the important work of the Alliance.
Spring 2015 News
Fall 2105 News